Florida Best Practice Psychotherapeutic Medication Guidelines for adults with major depressive disorder

Journal of Clinical Psychiatry

Volumn 78, Issue 6, 2017, Pages 703-713

  McIntyre, Roger S ^a,b,c   Suppes, Trisha ^d,e   Tandon, Rajiv ^f   Ostacher, Michael ^d,e  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

ADULT; CLASSIFICATION; CONSENSUS DEVELOPMENT; DEPRESSIVE DISORDER, MAJOR; EVIDENCE BASED MEDICINE; FLORIDA; HUMAN; PRACTICE GUIDELINE; STANDARDS;

ADULT; ANTIDEPRESSIVE AGENTS; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; DEPRESSIVE DISORDER, MAJOR; EVIDENCE-BASED MEDICINE; FLORIDA; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 85025086967     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.16cs10885     Document Type: Review

References (68)

1. Judd LL, Schettler PJ, Rush AJ, et al. A new empirical definition of major depressive episode recovery and its positive impact on future course of illness. J Clin Psychiatry. 2016;77(8):1065-1073.
2. Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med. 2013;10(11):e1001547. PubMed
3. Vos T, Barber RM, Bell B, et al; Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990.2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743-800. PubMed
4. Vancampfort D, Mitchell AJ, De Hert M, et al. Type 2 diabetes in patients with major depressive disorder: a metanalysis of prevalence estimates and predictors. Depress Anxiety. 2015;32(10):763-773. PubMed
5. Goldstein BI, Carnethon MR, Matthews KA, et al; American Heart Association Atherosclerosis; Hypertension and Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young. Major depressive disorder and bipolar disorder predispose youth to accelerated atherosclerosis and early cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2015;132(10):965-986. PubMed
6. Rush AJ. Isn't it about time to employ measurement-based care in practice? Am J Psychiatry. 2015;172(10):934-936. PubMed
7. Harding KJK, Rush AJ, Arbuckle M, et al. Measurement-based care in psychiatric practice: a policy framework for implementation. J Clin Psychiatry. 2011;72(8):1136-1143. PubMed
8. Malhi GS, Bassett D, Boyce P, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2015;49(12):1087-1206. PubMed
9. Bauer M, Severus E, Kohler S, et al; WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 2: maintenance treatment of major depressive disorder-update 2015. World J Biol Psychiatry. 2015;16(2):76-95. PubMed
10. Cleare A, Pariante CM, Young AH, et al; Members of the Consensus Meeting. Evidencebased guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015;29(5):459-525. PubMed
11. Gelenberg AJ. The American Psychiatric Association treatment guideline for major depressive disorder: process and content. Ann Gen Psychiatry. 2010;9(suppl 1):s46.
12. Zimmerman M, Clark HL, Multach MD, et al. Have treatment studies of depression become even less generalizable? a review of the inclusion and exclusion criteria used in placebo-controlled antidepressant efficacy trials published during the past 20 years. Mayo Clin Proc. 2015;90(9):1180-1186. PubMed
13. Driessen E, Hollon SD, Bockting CL, et al. Does publication bias inflate the apparent efficacy of psychological treatment for major depressive disorder? a systematic review and meta-analysis of US. PLoS One. 2015;10(9):e0137864. PubMed
14. Fiedorowicz JG, Endicott J, Leon AC, et al. Subthreshold hypomanic symptoms in progression from unipolar major depression to bipolar disorder. Am J Psychiatry. 2011;168(1):40-48. PubMed
15. Zimmerman M, McGlinchey JB, Posternak MA, et al. How should remission from depression be defined? the depressed patient's perspective. Am J Psychiatry. 2006;163(1):148-150. PubMed
16. Lam RW, Kennedy SH, Grigoriadis S, et al; Canadian Network for Mood and Anxiety Treatments (CANMAT). Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord. 2009;117(suppl 1):S26-S43. PubMed
17. Ostacher MJ, Tandon R, Suppes T. Florida Best Practice Psychotherapeutic Medication Guidelines for Adults With Bipolar Disorder: a novel, practical, patient-centered guide for clinicians. J Clin Psychiatry. 2016;77(7):920-926. PubMed
18. Manning JS, Jackson WC. Providing guidelineconcordant assessment and monitoring for major depression in primary care. J Clin Psychiatry. 2015;76(1):e3.
19. Chang SM, Bass EB, Berkman N, et al. Challenges in implementing The Institute of Medicine systematic review standards. Syst Rev. 2013;2:69. PubMed
20. Arnow BA, Blasey C, Williams LM, et al. Depression subtypes in predicting antidepressant response: a report from the iSPOT-D Trial. Am J Psychiatry. 2015;172(8):743-750. PubMed
21. Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR∗D report. Am J Psychiatry. 2008;165(3):342-351. PubMed
22. Suppes T, Silva R, Cucchiaro J, et al. Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, doubleblind, placebo-controlled study. Am J Psychiatry. 2016;173(4):400-407. PubMed
23. Guo T, Xiang Y-T, Xiao L, et al. Measurementbased care versus standard care for major depression: a randomized controlled trial with blind raters. Am J Psychiatry. 2015;172(10):1004-1013. PubMed
24. Coventry PA, Hudson JL, Kontopantelis E, et al. Characteristics of effective collaborative care for treatment of depression: a systematic review and meta-regression of 74 randomised controlled trials. PLoS One. 2014;9(9):e108114. PubMed
25. Trivedi MH, Greer TL, Grannemann BD, et al. TREAD: TReatment with Exercise Augmentation for Depression: study rationale and design. Clin Trials. 2006;3(3):291-305. PubMed
26. Mead GE, Morley W, Campbell P, et al. Exercise for depression. Cochrane Database Syst Rev. 2009; (3): CD004366.
27. McIntyre RS, Cha DS, Soczynska JK, et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety. 2013;30(6):515-527. PubMed
28. Bora E, Berk M. Theory of mind in major depressive disorder: a meta-analysis. J Affect Disord. 2016;191:49-55. PubMed
29. McIntyre RS, Lee Y. Cognition in major depressive disorder: a 'Systemically Important Functional Index' (SIFI). Curr Opin Psychiatry. 2016;29(1):48-55. PubMed
30. McIntyre RS, Soczynska JZ, Woldeyohannes HO, et al. The impact of cognitive impairment on perceived workforce performance: results from the International Mood Disorders Collaborative Project. Compr Psychiatry. 2015;56:279-282. PubMed
31. Jaeger J, Berns S, Uzelac S, et al. Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res. 2006;145(1):39-48. PubMed
32. Baune BT, Miller R, McAfoose J, et al. The role of cognitive impairment in general functioning in major depression. Psychiatry Res. 2010;176(2-3):183-189. PubMed
33. Baldessarini RJ, Lau WK, Sim J, et al. Duration of initial antidepressant treatment and subsequent relapse of major depression. J Clin Psychopharmacol. 2015;35(1):75-76. PubMed
34. Galling B, Calsina Ferrer A, Abi Zeid Daou M, et al. Safety and tolerability of antidepressant co-treatment in acute major depressive disorder: results from a systematic review and exploratory meta-analysis. Expert Opin Drug Saf. 2015;14(10):1587-1608. PubMed
35. Amick HR, Gartlehner G, Gaynes BN, et al. Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis. BMJ. 2015;351:h6019. PubMed
36. Bowie CR, Gupta M, Holshausen K, et al. Cognitive remediation for treatment-resistant depression: effects on cognition and functioning and the role of online homework. J Nerv Ment Dis. 2013;201(8):680-685. PubMed
37. Weitz ES, Hollon SD, Twisk J, et al. Baseline depression severity as moderator of depression outcomes between cognitive behavioral therapy vs pharmacotherapy: an individual patient data meta-analysis. JAMA Psychiatry. 2015;72(11):1102-1109. PubMed
38. Farahani A, Correll CU. Are antipsychotics or antidepressants needed for psychotic depression? a systematic review and metaanalysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment. J Clin Psychiatry. 2012;73(4):486-496. PubMed
39. Kudlow PA, Cha DS, McIntyre RS. Predicting treatment response in major depressive disorder: the impact of early symptomatic improvement. Can J Psychiatry. 2012;57(12):782-788.
40. Szegedi A, Jansen WT, van Willigenburg APP, et al. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a metaanalysis including 6562 patients. J Clin Psychiatry. 2009;70(3):344-353. PubMed
41. Thase ME, Youakim JM, Skuban A, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry. 2015;76(9):1224-1231. PubMed
42. Thase ME, Youakim JM, Skuban A, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry. 2015;76(9):1232-1240. PubMed
43. McIntyre RS, Gorwood P, Thase ME, et al. Early symptom improvement as a predictor of response to extended release quetiapine in major depressive disorder. J Clin Psychopharmacol. 2015;35(6):706-710. PubMed
44. Muzina DJ, Chambers JS, Camacho TA, et al. Adjunctive aripiprazole for depression: predictive value of early assessment. Am J Manag Care. 2011;17(12):793-801.
45. Zhou X, Keitner GI, Qin B, et al. Atypical antipsychotic augmentation for treatmentresistant depression: a systematic review and network meta-analysis. Int J Neuropsychopharmacol. 2015;18(11):pyv060. PubMed
46. Wang HR, Woo YS, Ahn HS, et al. Can atypical antipsychotic augmentation reduce subsequent treatment failure more effectively among depressed patients with a higher degree of treatment resistance. Int J Neuropsychopharmacol. 2015;18(8):pyv023. PubMed
47. Goldberg JF, Freeman MP, Balon R, et al. The American Society of Clinical Psychopharmacology survey of psychopharmacologists' practice patterns for the treatment of mood disorders. Depress Anxiety. 2015;32(8):605-613. PubMed
48. Rush AJ, Trivedi MH, Stewart JW, et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry. 2011;168(7):689-701. PubMed
49. Kedzior KK, Reitz SK, Azorina V, et al. Durability of the antidepressant effect of the highfrequency repetitive transcranial magnetic stimulation (rTMS) in the absence of maintenance treatment in major depression: a systematic review and meta-analysis of 16 double-blind, randomized, sham-controlled trials. Depress Anxiety. 2015;32(3):193-203. PubMed
50. Gaynes BN, Lloyd SW, Lux L, et al. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis. J Clin Psychiatry. 2014;75(5):477-489, quiz 489. PubMed
51. Vallejo-Torres L, Castilla I, González N, et al. Cost-effectiveness of electroconvulsive therapy compared to repetitive transcranial magnetic stimulation for treatment-resistant severe depression: a decision model. Psychol Med. 2015;45(7):1459-1470. PubMed
52. Guidi J, Tomba E, Fava GA. The sequential integration of pharmacotherapy and psychotherapy in the treatment of major depressive disorder: a meta-analysis of the sequential model and a critical review of the literature. Am J Psychiatry. 2016;173(2):128-137.
53. Meadows GN, Shawyer F, Enticott JC, et al. Mindfulness-based cognitive therapy for recurrent depression: a translational research study with 2-year follow-up. Aust N Z J Psychiatry. 2014;48(8):743-755. PubMed
54. Xu Y, Hackett M, Carter G, et al. Effects of lowdose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2016;19(4):pyv124. PubMed
55. Newport DJ, Carpenter LL, McDonald WM, et al; APA Council of Research Task Force on Novel Biomarkers and Treatments. Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am JPsychiatry. 2015;172(10):950-966. PubMed
56. Schatzberg AF. A word to the wise about ketamine. Am J Psychiatry. 2014;171(3):262-264. PubMed
57. Fond G, Loundou A, Rabu C, et al. Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology (Berl). 2014;231(18):3663-3676. PubMed
58. Perugi G, Angst J, Azorin J-M, et al; BRIDGE-IIMix Study Group. Mixed features in patients with a major depressive episode: the BRIDGEII-MIX study. J Clin Psychiatry. 2015;76(3):e351-e358. PubMed
59. Akiskal HS, Benazzi F, Perugi G, et al. Agitated "unipolar" depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy. J Affect Disord. 2005;85(3):245-258. PubMed
60. Benazzi F, Akiskal HS. Psychometric delineation of the most discriminant symptoms of depressive mixed states. Psychiatry Res. 2006;141(1):81-88. PubMed
61. Malhi GS, Lampe L, Coulston CM, et al. Mixed state discrimination: a DSM problem that won't go away? J Affect Disord. 2014;158:8-10. PubMed
62. Patkar A, Gilmer W, Pae C-U, et al. A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state. PLoS One. 2012;7(4):e34757. PubMed
63. Mitchell PB, Wilhelm K, Parker G, et al. The clinical features of bipolar depression: a comparison with matched major depressive disorder patients. J Clin Psychiatry. 2001;62(3):212-216, quiz 217. PubMed
64. Meyers BS, Flint AJ, Rothschild AJ, et al; STOPPD Group. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Arch Gen Psychiatry. 2009;66(8):838-847.
65. Etkin A, Patenaude B, Song YJC, et al. A cognitive-emotional biomarker for predicting remission with antidepressant medications: a report from the iSPOT-D trial. Neuropsychopharmacology. 2015;40(6):1332-1342. PubMed
66. Schatzberg AF, DeBattista C, Lazzeroni LC, et al. ABCB1 genetic effects on antidepressant outcomes: a report from the iSPOT-D Trial. Am J Psychiatry. 2015;172(8):751-759. PubMed
67. Dubovsky SL. The usefulness of genotyping cytochrome P450 enzymes in the treatment of depression. Expert Opin Drug Metab Toxicol. 2015;11(3):369-379. PubMed
68. Berm EJJ, Hak E, Postma M, et al. Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial). Trials. 2015;16:37.